NCT03063632 - Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 14, 2017

Primary Completion Date

April 8, 2021

Study Completion Date

March 14, 2023

Conditions

Metastatic Myxoid LiposarcomaMetastatic Round Cell LiposarcomaMetastatic Synovial SarcomaRecurrent Mycosis Fungoides and Sezary SyndromeRefractory Mycosis Fungoides and Sezary SyndromeStage IB Mycosis Fungoides and Sezary Syndrome AJCC v7Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7Unresectable Synovial Sarcoma

Interventions

BIOLOGICAL

Interferon Gamma-1b

Given SC

OTHER

Laboratory Biomarker Analysis

Ancillary studies

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

19104

University of Pennsylvania/Abramson Cancer Center, Philadelphia

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

63110

Washington University School of Medicine, St Louis

94304

Stanford Cancer Institute Palo Alto, Palo Alto

98109

FHCC South Lake Union, Seattle

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH